Clinical trial
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
NCT05397600 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
- Lead sponsor
- Laboratoires Thea
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 22, 2022
- Completion date
- March 7, 2024
- Enrollment
- 684 (actual)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.